Premium
Low‐level lead exposure increased bioavailability of nitric oxide mediated by angiotensin II and PI3K/AKT pathway in rat aorta (700.2)
Author(s) -
Fiorim Jonaina,
Ribeiro Rogério,
Azevedo Bruna,
Simões Maylla,
Santos Leonardo,
Padilha Alessandra,
Alonso Maria,
Salaices Mercedes,
Stefa Ivanita,
Vassallo Dalton
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.700.2
Subject(s) - bioavailability , losartan , nitric oxide , chemistry , angiotensin ii , wortmannin , phenylephrine , pi3k/akt/mtor pathway , endocrinology , lead acetate , protein kinase b , medicine , lead (geology) , pharmacology , toxicity , blood pressure , signal transduction , biochemistry , biology , paleontology
We previously demonstrated that 7‐day exposure with a low concentration of lead acetate increases blood pressure (BP) and nitric oxide (NO) bioavailability, which could be a compensatory mechanism in the initial stages of lead exposure.We investigated the involvement angiotensin II and PI3K/AKT pathway in this increased NO bioavailability. Wistar rats were treated with lead (1st dose 4 μg/100g and, subsequent doses 0.05 μg/100g, i.m cover daily loss) or vehicle. After lead treatment, blood levels were of 9.98μg/dL. In aortic rings from lead‐treated rats, phenylephrine (PHE 10‐10‐10‐4M) contractile responses were reduced; L‐NAME (LN‐10µM) increased PHE responses more in lead‐treated rats than untreated rats. Wortmannin (WT‐0,1µM) and PD123319 (PD‐1µM) normalized PHE responses in treated rats, and in presence of either WT, PD or losartan (LOS) that effect of LN on reactivity from lead treated group was blunted. Lead also increased release of NO, which was blocked by LOS, WT and PD. Our results suggest the involvement of angiotensin II and PI3K/AKT pathway in increased NO bioavailability in lead rats. This might be an alternative way to increase the NO bioavailability, as a compensatory mechanism against the increased SBP in the early stages of lead exposure. Grant Funding Source : CAPES, CNPq and FAPES.